Refine by
Retinal Ganglion Cell Suppliers & Manufacturers
4 companies found
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tropisetron Hydrochloride (SDZ-ICS-930) is an effective neuroprotective agent that acts as a 5-HT3 receptor antagonist, a calmodulin inhibitor, and an α7-nAChRreceptor agonist, with an IC50 of 70.1 nM for the 5-HT3 receptor. Tropisetron ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
Accelerated in vitro evaluation of retinal toxicity. Newcells offers a fast and reliable retinal drug toxicity in vitro testing service using complex models developed in house: retinal organoids and RPE. The retinal toxicity service evaluates how ...
based inCottesloe, AUSTRALIA
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision ...
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide ...